As a Global Program Executive Director with Novartis Pharmaceuticals in Basel, Switzerland, Anthony focuses on the operations of developing late stage therapeutics and preparing for global launch. He is also tasked with building our therapeutic pipeline, specifically in the fields of immunology, hepatology and dermatology, so is always interested in assets coming out of venture funds to push to the Global BD&L team. He was also a part of the team that developed and launched Entresto for patients with heart failure, so am also interested in venture assets focused on cardiology and metabolism.
Previously, he was a Principal with BioVentures Investors in Boston where he led due diligence efforts and held Board seats with companies in the BVI2 and BVI3 Funds. Anthony led a number of investments and participated actively in efforts with CardioSolutions, Claros Diagnostics, Cylene Pharmaceuticals, Enanta Pharmaceuticals, Spirus Medical, Hydra Biosciences, Rcadia Medical Imaging, Hydrocision, Verax Biomedical, Vital Sensors, and Momelan Technologies.
Before venture, he was a strategy consultant with L.E.K. Consulting, working with pharmaceutical, biotech, and private equity clients on projects that addressed asset valuation, strategic planning, and investment due diligence.
Education, Personal, and Fellowship
Anthony holds an MD from the Johns Hopkins School of Medicine where he focused on internal medicine and regenerative research, an MBA from the Kellogg School of Management where he focused on strategy, finance and decision analysis, and a BS in Mechanical and Aerospace Engineering from Syracuse University.
Prior to medical school, Anthony served his country (USA) an officer in the United States Air Force as an aviator in the F-111 airframe. He was discharged from the USAF having received the Air Force Achievement Medal for Leadership.
He was also an active volunteer for the Southwest Corridor Park Conservancy, part of Frederick Law Olmsted's Emerald Necklace, a series of parks, in Boston.
A member of Class 14, Anthony served his fellowship under mentor Marc Goldberg at BioVentures Investors.